𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy of long-term lanreotide treatment in patients with acromegaly

✍ Scribed by Yoel Toledano; Liat Rot; Yona Greenman; Sophia Orlovsky; Yulia Pauker; David Olchovsky; Achia Eliash; Orit Bardicef; Ofa Makhoul; Gloria Tsvetov; Michal Gershinsky; Odile Cohen-Ouaqnine; Rosane Ness-Abramof; Zaina Adnan; Jacob Ilany; Hadassah Guttmann; Mazal Sapir; Carlos Benbassat; Ilan Shimon

Publisher
Springer US
Year
2009
Tongue
English
Weight
282 KB
Volume
12
Category
Article
ISSN
1386-341X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Treatment of carcinoid syndrome : A pros
Treatment of carcinoid syndrome : A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance
✍ Dermot O'Toole; Michel Ducreux; Gilles Bommelaer; Jean-Louis Wemeau; Olivier Bou πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 78 KB

## BACKGROUND. The somatostatin analogues lanreotide and octreotide have previously been shown to be effective in controlling flushing and diarrhea in patients with carcinoid syndrome. As lanreotide requires injection only every 10 days, compared with twice-daily injections of octreotide, a direct

Long-term treatment with long-acting ris
Long-term treatment with long-acting risperidone in Korean patients with schizophrenia
✍ Moon-Soo Lee; Young-Hoon Ko; Sang-Hoon Lee; Yong-Jin Seo; Seung-Hyun Kim; Sook-H πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 146 KB

## Abstract ## Objectives We evaluated the efficacy and safety of long‐acting risperidone for 48‐week period in Korean patients. ## Methods This was a non‐randomized, open‐label, single‐centered, 48‐week study. Each of the participants visited the hospital every 2 weeks, and injections were give